LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Vaxcyte Inc

Gesloten

SectorGezondheidszorg

30.63 0.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.41

Max

30.77

Belangrijke statistieken

By Trading Economics

Inkomsten

-26M

-167M

Werknemers

414

EBITDA

14M

-162M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+245.89% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-397M

4B

Vorige openingsprijs

30.53

Vorige sluitingsprijs

30.63

Nieuwssentiment

By Acuity

50%

50%

160 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Vaxcyte Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2025, 14:19 UTC

Belangrijke Marktbewegers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3 sep 2024, 17:22 UTC

Top Nieuws

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Peer Vergelijking

Prijswijziging

Vaxcyte Inc Prognose

Koersdoel

By TipRanks

245.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 106.5 USD  245.89%

Hoogste 163 USD

Laagste 50 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vaxcyte Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

28.09 / 34Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

160 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.